- Home
- » Tags
- » Leuprorelin
Top View
- Firmagon, INN-Degarelix
- A New Sustained-Release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients with Prostate Cancer
- Leuprorelin- Containing Depot Medicinal Products
- Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer
- Degarelix DTC Summary
- The Role of Gonadotropin-Releasing Hormone (Gnrh) in Endometrial Cancer
- A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
- Summary of Product Characteristics
- Role of Gonadotropin-Releasing Hormone (Gnrh) in Ovarian Cancer
- Leuprorelin (Prostap®) for the Treatment of Prostate Cancer
- Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer
- Medical Management of Gender Transition
- Leuprorelin Acetate (N=142)
- Gonadotropin-Releasing Hormone (Gnrh) Analogues in Prostate Cancer
- Gonadorelin Analogues for Endometriosis
- Australian Public Assessment Report for Leuprorelin Acetate
- Elagolix for Endometriosis
- New Zealand Consumer Medicine Information
- Leuprorelin Acetate in Prostate Cancer: a European Update
- Supposed Pituitary-Production of Human Chorionic Gonadotropin Induced by Androgen Deprivation Therapy ______
- Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy Ayman Al‑Hendy, M.D., Ph.D., Andrea S
- 203696Orig1s000
- Safety and Clinical Efficacy of a New 6-Month Depot Formulation of Leuprorelin Acetate in Patients with Prostate Cancer in Europe
- Comparative Analysis of Luteinizing Hormonereleasing Hormone
- Gonadorelin Analogues Prescribing Support Information
- Is High-Dose Leuprorelin Acetate Effective and Safe in Asian Men with Prostate Cancer? an Open-Label, Non-Comparative, Multi-Center Clinical Trial
- Unusual Side Effect from a Luteinizing Hormone-Releasing Hormone Agonist, Leuprorelin, in the Treatment of Prostate Cancer
- Elagolix for Treating Endometriosis
- Randomised Crossover Trial to Assess the Tolerability of LHRH Analogue Administration
- Leuprorelin Acetate for the Prevention of Menstrual Bleeding in Premenopausal Women Undergoing Stem Cell Transplantation
- A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix Versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy Rashid K
- Elagolix: First Global Approval
- Degarelix Acetate (Firmagon®)
- Hormone Therapy for Transgender Women
- A Guide to Hormone Therapy for Trans People
- Australian Pi – Lucrindepot® and Lucrin Depot® Paediatric
- Package Leaflet: Information for the User
- Leuprorelin-Containing Depot Medicinal Products
- New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines
- Gonadotropin-Releasing Hormone Agonists- Eligard®, Fensolvi® (Leuprolide Acetate), Lupron®, Lupron- Depot®, Lupron Depot - Pe D® , Lupaneta® (Leuprolide
- Data Sheet 1
- Orilissa (Elagolix) Policy Number: C15417-A
- Elagolix for Treating Endometriosis
- ENDOMETRIOSIS Published by Elsevier Science Inc
- Leuplin Depot 3M 11.25 Mg S.C. Injection "TAKEDA" Leuprolide Acetate for Injection
- Lupron (Leuprolide Acetate) Injection, Solution [Abbott Laboratories]
- 25 November 2020 Gnrh Antagonist TAK-385 Announcement of Phase 3
- New 0Ral Gonadotropin-Releasing Hormone (Gnrh) Antagonist
- 213388Orig1s000
- Report on the Deliberation Results December 4, 2018 Pharmaceutical
- Optimal Feminizing Hormone Treatment in Transgender People
- Hormone Therapy in Gender Dysphoria AMBER0
- Comparative Clinical Effectiveness of Elagolix for Endometriosis : Research Protocol Background, Objectives, and Research Questions
- Relugolix, an Oral Gonadotropin-Releasing Hormone